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Despite decades of use as the “gold standard” in the detection of prostate cancer, the optimal biopsy regimen is still not
universally agreed upon. While important aspects such as the need for laterally placed biopsies and the importance of apical
cancer are known, repeated studies have shown signiﬁcant patients with cancer on subsequent biopsy when the original biopsy
was negative and an ongoing suspicion of cancer remained. Attempts to maximise the eﬀectiveness of repeat biopsies have
given rise to the alternate approaches of saturation biopsy and the transperineal approach. Recent interest in focal treatment
of prostate cancer has further highlighted the need for accurate detection of prostate cancer, and in response, the introduction
of transperineal template-guided biopsy. While the saturation biopsy approach and the transperineal template approach increase
the detection rate of cancer in men with a previous negative biopsy and appear to have acceptable morbidity, there is a lack
of clinical trials evaluating the diﬀerent biopsy strategies. This paper reviews the evolution of prostatic biopsy and current
controversies.
1.Introduction
Prostate cancer is now recognized as one of the major
medical problems facing the male population. In Europe,
with an annual incidence of214 casesper 1000men, prostate
cancer represents the most common solid tumour aﬀecting
men, having surpassed lung and colorectal cancers [1], and
it is the second most common cause of cancer death in men
[2].
In 2008, an estimated 186,320 men were diagnosed with
prostate cancer and 28,600 were expected to die from the
disease in the USA [2].
Despite the rapid development of imaging and extensive
clinical evaluation of PSA and its derivates, as well as novel
prostate cancer biomarkers, prostate biopsy remains up to
this day the only diagnostic test for the detection of cancer.
However, far from a standardized practice, prostate biopsy
is still evolving. Indeed, the ideal technique, the so-called
biopsy “gold standard”, is still to be fully deﬁned.
2.LimitationsofSextantBiopsy
Following the landmark study of Hodge and colleagues
in 1989 [3], demonstrating the superiority of systematic
TRUS biopsies compared to digitally directed sampling,
TRUS-guided biopsies became the accepted standard for
diagnosis of prostate cancer. In this scheme, 6 parasagital
cores (biopsies from apex, middle, and base of each lobe)
were obtained in a systematic randomized fashion. However,
sampling was clearly limited, and subsequent studies have
demonstrated a high false-negative rate of between 15 and
31% [4–7].
Inanexvivomodel,where90patientsundergoingradical
prostatectomy for clinically localized disease underwent
sextant biopsy immediately afterremoval ofthe gland, Svetec
et al. demonstrated a 45.6% false-negative rate [8].
In the same year, Rabbani et al. studied the incidenceand
clinical signiﬁcance of false-negative sextant biopsies in 118
patients with proven cancer, who underwent repeat sextant2 Prostate Cancer
prostate biopsy before prostatectomy. Sextant biopsies were
negative in 27/118 (23%) cases, all of these representing
signiﬁcant cancers [4].
Stochastic computer simulation models of ultrasound-
guided biopsies, using mathematically reconstructed radical
prostatectomy specimens, developed at the M.D. Ander-
son Cancer Center [9] and the University of Colorado
[10], consistently demonstrated false-negative biopsy rates
of 27% and 26.8%, respectively. Two main conclusions
were drawn from these studies: ﬁrst, sampling limitations
by standard sextant biopsies missed “signiﬁcant” prostate
tumours; second, improved biopsy schemes for detection of
low-volume cancers should include prostate gland volume
and tumour distribution. In particular, biopsies of the
transition zone (TZ), midline peripheral zone (PZ), and
inferior portion of the anterior horn of the peripheral zone
were highlighted, as evidenced by the 96% cancer detection
rate for tumour volumes >0.5cc when a 10-core biopsy
scheme incorporating these areas was implemented [9].
In the light of the evidence from these and other similar
studies [5, 11], the nineties saw a move away from the
sextant biopsy, no longer considered as the “gold standard”
for prostate cancer diagnosis. In an attempt to decrease
false-negative rates, new approaches rapidly emerged: (a)
in parallel to the technological improvements with modern
US, more accurately targeted biopsies were assessed; (b)
to avoid sampling limitations, number of cores rapidly
increased; ﬁnally, (c) anatomical considerations guided the
development of new biopsy schemes incorporating more
lateral biopsies as well as the transitional and apical zones.
3.Limitationsof TargetedBiopsies
Rapid technological advances in ultrasound (US) imaging,
in particular the introduction of the 7.5MHz probe in 1980,
allowed a more accurate description of the prostate anatomy,
with a much clear deﬁnition of the transitional-peripheral
zone interface and made possible a more selective targeting
of intraprostatic lesions.
In 1997, Norberg et al. evaluated the sensitivity of
targeted biopsies and compared it with the standard sextant
protocol in 512 consecutive patients with suspected cancer.
Patients had 8 or 10 standardized biopsy samples depending
on the size of the gland. Additional targeted biopsies were
taken from hypoechoic or hyperechoic lesions. Sensitivity
was 59% for focal lesions detected by TRUS, 85% to 97%
for diﬀerent combinations of systematic biopsy samples, and
93% to 98% for a combination of systematic and targeted
biopsies. Whereas the sensitivity for the standard sextant
protocolwas85%,theaddition oftargetedbiopsiesincreased
the sensitivity to 93% [6]. Further evidence for a targeted
approach has been reported by other contemporary studies
[12, 13].
Toietal.reportedresultson7,426transrectalultrasound-
directed biopsies performed at the Princess Margaret Hos-
pital (Toronto, Canada). Patients underwent systematic
biopsy with additional sampling of visible suspicious lesions.
Overall, cancer detection rate was 43.9%. The presence
of a sonographic lesion increased the likelihood of cancer
detection (57.8% versus 30.8%). Targeted biopsies from
these lesions had a signiﬁcantly greater median percent of
the core involved with cancer (50% versus 10%, P<. 001)
and grade (presence of Gleason ≥7 in 69.3% versus 28.3%,
P<. 001) [14].
Lee et al. enrolling 350 patients with ultrasound detected
lesions, evaluated the diagnostic eﬃcacy of TRUS-guided
targeted prostatic biopsies and proposed a new scoring
system for the prediction of malignancies, based on lesion
characteristics depicted on TRUS. Utilizing this scoring
system for cancer detection, the authors reported a positive
predictive value of 80% when applied to the test set
[13].
Evaluatingthe signiﬁcance of suspicious lesions atTRUS,
Shim et al. studied a cohort of 1,009 men undergoing
biopsy for suspected cancer. Overall, cancer detection rate
was 26.3%, being higher in patient with suspicious lesions
(33.2% versus 21.5%, P<. 001). The positive predictive
valueofadditionallesion-directedbiopsywas18%.However,
patients who had positive cores on lesion-directed biopsies,
all were also found to have positive cores on random
biopsies, and no patient had positive cores only on lesion-
directed biopsies, questioning the real value of these schemes
[15]. Supporting those ﬁndings, Onur et al. prospectively
studied 3,912 patients undergoing sextant plus targeted
biopsiesofhypoechoiclesions(68%).Theauthorsconcluded
that despite the higher prevalence of cancers discovered
in prostates with hypoechoic areas, the hypoechoic lesion
itself was not associated with increased cancer prevalence
compared with biopsy cores from isoechoic areas [16].
Further contemporary studies, as well as recent evidence,
question the value of targeted biopsies, which can at least
be partly explained by the low speciﬁcity of ultrasound in
characterising prostatic lesions [17]. The classic hypoechoic
area in the peripheral zone is not always necessarily present
[18]. Moreover, Ellis and coworkers noted that 37.6% of
their detected cancers were diagnosed in isoechoic areas of
the prostate [19]. A strategy of performing biopsy of only
hypoechoic sectors will miss 24.6% of patients with prostate
cancer [19]. A recent study by Spajic et al. in a cohort
of 200 patients undergoing TRUS for clinically suspected
cancer reported an incidence of isoechoic, hypoechoic, and
hyperechoic lesions of 49%, 41.5%, and 9.5%, respectively.
There was an overall cancer detection rate of 33%. Among
patientswith cancer, isoechoic, hypoechoic, and hyperechoic
lesions were present in31.8%, 60.6%, and 7.6%, respectively.
Interestingly, the Gleason score of hyperechoic cancers was
higher when compared with isoechoic and hypoechoic
cancers [20].
4.Increasing the Number ofCores:
ExtendedProtocols
Withthe obvioussampling limitations oftheoriginal sextant
biopsy protocol, clinicians optimized biopsy schemes by
increasing thenumber of cores. Intuitively,one would expect
that increasing the sample size and including areas not
sampled by the standard 6-core scheme would increase the
cancer detection rate.Prostate Cancer 3
An ex vivo study by Fink and coworkers, comparing
sextant versus 10-core biopsy template in 91 prostatectomy
glands demonstrated a higher detection rate for both initial
(78% versus 60%) and repeated (90% versus 75%) biopsies,
with the 10-core scheme [21].
Many published studies and literature reviews have
demonstrated this presumption, giving further evidence of
the importance of sampling the lateral and apical peripheral
zones [22, 23]. Such extended schemes ranging from 10 to
18 cores have consistently reported cancer detection rates in
the order of 40% by complementing the standard sextant
template with added coresdirected to the far lateral and mid-
regionsofthegland[24,25],thebaseandmiddleofeachlobe
[26, 27], anterior TZ, middle PZ, and anterior horn [28].
In a study of 396 consecutive patients undergoing
standard sextant plus laterally directed peripheral zone
biopsies, Gore et al. reported a cancer detection rate
of 40.4%. Furthermore, subset analysis of diﬀerent core
combinations demonstrated that a 10-corescheme including
laterally directed cores at the base, mid-gland, and apex with
midlobarbaseand apicalsampling detected98.5%ofcancers
[24].
In 2006, Eichler and colleagues published a systematic
review and meta-analysis of published studies with a total of
20,698 patients. Data was pooled from 68 studies comparing
a total of 94 extended schemes with the sextant standard,
demonstrating once more that laterally directed cores sig-
niﬁcantly increase the diagnostic yield. In particular, 12-
core with additional laterally directed cores detected 31%
more cancers than the sextant scheme, with a comparable
complication rate. Interestingly, no further beneﬁt was seen
in extended schemes with 18 to 24 cores, whereas the adverse
event proﬁle was poor with these templates. The authors
concluded that more than 12 cores added no signiﬁcant
beneﬁt [29].
In agreement with Eichler’s meta-analysis, two recently
published studies critically reviewing the optimal biopsy
strategies have further supported the use of extended 10- to
14-core biopsy schemes as the new “gold standard” for ﬁrst-
time prostate biopsy [30, 31].
Nevertheless, these and other contemporary published
studies have also highlighted the need for more intensive
strategies in patients undergoing repeated biopsies. In this
setting, despite of extended schemes, prostate biopsy is still
associated with signiﬁcant “false-negative” results as evi-
denced by the signiﬁcant percentage of men with persistent
clinical suspicion, who will be diagnosed at subsequent
biopsy (range: 18.8 to 55.5%) [32–36].
5.IndicationsandOptimal
Scheme forRebiopsy
In spite of the evidence for rebiopsy in patients with
previous benign histology and persistent clinical suspicion,
theindications,therequirednumber ofcores,and evenmore
so, the optimal biopsy scheme remain controversial.
Supported by clinical evidence and endorsed by the
AUA and the EAU, it is common practice to oﬀer repeated
biopsy to patients with initial negative biopsy and persistent
clinical suspicion of cancer, dictated by abnormal DRE,
persistent elevation of PSA, and initial histology. However,
better understanding of the cancer biology and clinical
signiﬁcance of high-risk lesions (HGPIN and ASAP), as
well as rapid changes in the management of patients with
prostatic malignancy, particularly organ-conﬁned disease,
has dramatically widened the spectrum.
5.1. ASAP. Atypical small acinar proliferation (ASAP), a
suspicious small focus of atypical glands, but with insuﬃ-
cient architectural and/or cytological criteria for deﬁnitive
diagnosis [37], is found in approximately 5% of ﬁrst-time
prostate biopsies, and it has been associated with positive
second biopsies in approximately 40% of cases [38]. In a
recent study of patients with ASAP at initial 10- or 12-
core biopsy, Scattoni and coworkers have reported a cancer
detection rate of 39%, 35%, and 21% at ﬁrst, second, and
third rebiopsy, respectively. When HGPIN was associated
with ASAP (17%), the cancer detection rate was higher
(50%) [39].
5.2. HGPIN. While low-grade prostatic intraepithelial neo-
plasia (PIN) is not reported, the presence of isolated high-
grade PIN (HPIN) should be reported in all biopsy spec-
imens [40]. High-grade prostatic intraepithelial neoplasia
(HGPIN) is characterized by architecturally normal ducts
and acini lined with abnormal cells with prominent nucleoli
and nucleomegaly [37, 41]. Although reports with diﬀerent
schemes have varied widely, Epstein and Herawi reported
an incidence of HGPIN at ﬁrst biopsy in the order of 5–
8%. The median risk for cancer at second biopsy was 24.1%
[38]. With a risk no diﬀerent from that in patients with
a benign histology, the authors concluded that immediate
repeat biopsy is not necessary [38, 40]. However, De Nunzio
and coworkers studied a cohort of 650 men undergoing
ﬁrst-time biopsy and detected HGPIN in 22%. With an
overall cancer detection rate of18.8%, the authors correlated
the cancer risk with the number of cores involved and
recommended repeated biopsy when more than 4 cores are
involved [34]. Furthermore, a recent study by Schoenﬁeld
et al. evaluating initial saturation biopsy has also detected a
high cancer rate (80%) following the ﬁnding of multifocal
HGPIN at ﬁrst biopsy [37].
Borboroglu and coworkers reported an incidence of
HGPIN or ASAP of 9.8% in a cohort of 1,391 men
undergoingﬁrstbiopsy.Cancerdetectionrateatrebiopsywas
47%. Interestingly, the initial biopsy site matched the sextant
location of cancer on repeat biopsy in 47%. The authors
concluded that having targeted biopsy of the area with
HGPIN and/or ASAP would have missed 53% of cancers
[42].
Far from deﬁnitive, the indications for rebiopsy continue
to evolve, as the technique itself does. Most clinicians will
oﬀer rebiopsy to patients with persistent clinical suspicion
based on persistently high or rising PSA, abnormal DRE,
and suspicious TRUS ﬁndings. Equally, most clinicians will
rebiopsy patients with ASAP, potentially HGPIN, and of
course, all those cases with inconclusive histology reports.
Implementation of active surveillance protocols, and more4 Prostate Cancer
recently, a move towards focal therapies has made clini-
cians reevaluate current practices and explore even more
exhaustive schemes such as “saturation biopsy” and also,
based on anatomical considerations, a renewed interest on
the transperineal approach.
6.The RoleandLimitationsof
SaturationBiopsies
In the absence of a standard template for repeated prostate
biopsy and with a clear trend towards larger samplings of
the gland in the repeated setting, several groups focused the
attentiononmore extensive protocolswith the aim to reduce
false-negative rates.
In 2000, Borboroglu and coworkers reported their expe-
rience on 57 men with at least one previous negative sextant
biopsy (mean: 2.1; range: 1 to 4), who underwent extensive
transrectal ultrasound-guided biopsy. Under intravenous
sedation, an averageof22.5cores(range:15to31)wastaken.
Withanoverallcancerdetectionrateof30%,malignancywas
identiﬁed in 47% of men with previous HGPIN or ASAP.
The authors reported 6 cases of urinary retention and 1
case of rectal bleeding [43]. One year later, Stewart coined
the term “saturation biopsy”. In this study, 224 men with
previous negative sextant biopsies (range: 1 to 7) underwent
an extensive protocolincludinga mean of 23 cores (range: 14
to 45), reporting an improved cancer detection rate of 34%.
The overall complication rate was 12%, with haematuria
being the most common event [44].
For the last 10 years, the clinical role of “saturation”
in the rebiopsy setting has been further scrutinized in
several published series, with reported cancer detection rates
ranging from 13.5 to 45% [43–52].
De La Taille and coworkers [46]p r o s p e c t i v e l ye v a l u a t e d
the beneﬁt of added cores in a 21-core saturation scheme
comprising sextant biopsies at a 45◦ angle, 6 PZ cores at an
80◦ angle,6TZcoresand3biopsiesinthemidline peripheral
zone. With 303 men enrolled, the cancer detection rate using
sextant biopsies, 12 cores (sextant plus lateral biopsies), 18
cores (sextant plus lateral plus TZ biopsies), and 21 cores
(sextant plus lateral plus TZ, plus midline biopsies) was
22.7%, 28.3%, 30.7%, and 31.3%, respectively. Furthermore,
subset analysis correlating positive biopsy cores with ﬁnal
histology in 150 prostatectomy specimens demonstrated
higher accuracy of the saturation protocol in predicting T3
disease and positive margins [51].
Fleshner and Klotz [45] evaluated a saturation protocol,
involving 24 PZ cores, 6 to 12 TZ cores, and 2 transurethral
samples, in a highly prebiopsied cohort of 37 men and
reported a cancer detection rate of 13.5%, with all malig-
nancies detected in the PZ cores. Rabets et al. performed
saturation prostate biopsy in 116 patients with at least 1
prior negative biopsy and reported an overall detection
rate of 29%. Interestingly, a 64% detection rate was noted
when a patient had undergone a single prior sextant biopsy.
They analysed cancer detection rates by type of biopsy and
by number of previous biopsies. Cancer detection rates
following sextant and ≥10-core biopsies were 41% and
24%, respectively. Cancer detection rate was 33% following
single biopsy compared to 24% for multiple biopsies
[52].
On review of the literature, the question remains of
how many cores are optimal on saturation biopsy. Published
protocols have incorporated very variable number of cores,
usually between 20 to 30, and have reported overlapping
results. It seems logical to sample the prostate gland with
as u ﬃciently large number of cores, yet one must attempt
to strike a balance with unwanted morbidity. This has
been recently evidenced by Simon et al. who utilized an
“extensive saturation” biopsy protocol involving a median of
64 cores (range: 39 to 139). With 40 patients enrolled, cancer
detection rate was 45%. The authors concluded that there
is no signiﬁcant increase in the cancer detection rate in an
extensive saturation-biopsy regimen compared to published
series with fewer cores, but the morbidity increased [49].
Several studies have proposed that the use of saturation
biopsies should not be restricted to patient with previous
negative biopsies but should be extended to be used at
initial biopsy. However, data have shown that the detection
rate using initial saturation biopsies was not signiﬁcantly
increased compared to extended schemes. In 2006, Jones et
al. [53] published their results on a cohort of 139 patients
(PSA ≥ 2.5ng/dl) undergoing ﬁrst-time biopsy compared
to those of 87 patients who had previously undergone 10-
core initial biopsies. Cancer detection rates were 44.6% and
51.7%, respectively. Complication rates were comparable.
The authors concluded that although saturation prostate
biopsy improved cancer detection in men with suspicion
of cancer following a negative biopsy, it did not appear to
oﬀer beneﬁt as an initial biopsy technique. These ﬁndings
have been further supported by a recently published study
by Lane et al. [54], of 257 men undergoing initial saturation
biopsy, with a reported 43% cancer detection rate. In the
147 cases with negative initial saturation biopsy, and with a
median follow-up period of 3.2 years, the false-negative rate
on subsequent prostate biopsy (24%) was equivalent to that
following traditional prostate biopsy.
In the light of these data and those from other groups,
it is now widely accepted that saturation biopsy has to be
consideredonlyintherepeatsetting[30,31,55,56].Further-
more, even in the repeat setting transrectal saturation biopsy
can miss potentially signiﬁcant cancer in poorly sampled
prostate regions, in particular the apical region. Also, the
limitations of transrectal sampling need to be considered
when planning focal therapeutic approaches, which require
a “perfect” spatial delineation of the target tumour. This has
encouraged clinicians to pursue transperineal approaches.
7.The TransperinealApproach:
Deﬁnitionand Rationale
Far from a novel technique, transperineal needle biopsy
of the prostate was ﬁrst described by Peck back in 1972
[57]. In 1990, Clements and coworkers published a series
of 143 consecutive patients with suspicious US and/or
digital rectal examination (DRE) and reported a cancer
detection rate of 34.3% [58]. However, initial reports were
restricted to patients unsuitable for the standard transrectalProstate Cancer 5
approach. Several published studies demonstrated the safety
and eﬃcacy of transperineal needle biopsy in patients with
previous proctocolectomy or abdominoperineal resection
[59–61]. While initial series employed transurethral ultra-
sound guidance [60, 62], Filderman and Jacobs described
in 1994 the technique of transperineal ultrasound-guided
transperineal prostate biopsy [63].
In a comparative study on 20 men with known cancer
undergoing biopsy immediately before radical prostatec-
tomy, Shinghal and Terris reported a 10% cancer detection
rate with a transperineal US-guided 6-core transperineal
biopsy template, compared to a sensitivity of 65% with
TRUS-guided sextant biopsies [64]. This result can be
in part explained simply by the imaging limitations of
transperineal US. Indeed, a recent study has also indicated
the technical superiority of TRUS for visualisation and
measurement of the prostate gland when compared to
transperineal US [65]. Furthermore, the sampling size on
thatstudy made theinterpretationdiﬃcult.Inarecentstudy,
Terris and coworkers reviewed 28 patients with elevated
PSA (median = 9.5ng/ml) and previous abdominoper-
ineal resection, undergoing US-guided transperineal biop-
sies, and reported a cancer detection rate of 82% [66].
The impact of prostate volume and the optimal number
of cores in patients undergoing ﬁrst-time transperineal
biopsy has been further emphasized in contemporary series
[67, 68].
Despite the initial hesitancy, TRUS-guided systematic
prostate biopsies by the transperineal approach have con-
tinued to evolve. Indeed, the last decade, driven by the
superior sampling of the prostate apex [69]a n da n t e r i o r
region [70], has seen an unprecedented renewed interest for
these schemes.
Ficarra and colleagues [67] compared the performance
of diﬀerent transperineal schemes in a cohort of 480
consecutive patients (PSA = 2.5–20ng/ml) undergoing 14-
core TRUS-guided transperineal prostate biopsy, including
12 cores in the peripheral and two in the transitional
zone. Detection rates were subanalysed for 14, 12, 10, 8,
and 6 cores, by exclusion of pairs of cores and further
stratiﬁed according to TRUS volume. While the standard
sextant biopsies detected 35.2% of cancers, the 8- and 10-
core schemes yielded detection rates of 37.1–38.8% and of
39.6–40.8%,respectively.Importantly,withprostatevolumes
<30cc, the detection rate of the 14-core scheme (43.8%)
was not statistically diﬀerent to that obtained with the 8-
peripheral core protocol. In patientswith 30.1–50ccprostate
volume a 12-peripheral core scheme was equivalent to a 14-
coresampling.Above50cc,eventhe14-corescheme(24.2%)
was found to be insuﬃcient, the authors recommending
larger number of cores for larger glands.
Several series evaluating diﬀerent transperineal schemes
in the ﬁrst-time biopsy setting have been published in the
last 10 years, reporting cancer detection rates in the order
of 18.8–72.1% and 24–75.4%, when employing 6 and 12
cores, respectively [68, 71–75]. More extensive schemes have
alsobeenevaluatedinthissetting,reporting cancerdetection
rates of 36% with 14 cores [76] and up to 49% with 18 cores
[77, 78].
Roccoand coworkersat the European Institute of Oncol-
ogy in Milan evaluated the sensitivity and detection rate of
12-core transperineal biopsiesi n6 3p a t i e n t sn o tp r e v i o u s l y
investigated for prostate cancer (median PSA = 1.2ng/ml),
undergoingradicalcystoprostatectomyforbladdercancer.In
this cohort, 17.2% of biopsies were positive, resulting in an
overallsensitivity of32.3%.However,sensitivity forclinically
signiﬁcant cancers was 75% [79].
8.Comparisonof Transperinealand
Transrectal BiopsySchemes
Few studies have directly compared the performance of
the transrectal and transperineal approaches in the sextant
a n de x t e n d e ds e t t i n g s .I na nex vivo study, Vis et al.
compared US-guided sextant transverse (transrectal) biopsy
and subsequent sextant longitudinal (transperineal) biopsy
on40radical prostatectomy specimens. Of40 cancers,82.5%
were redetected by the transperineal and 72.5% by the
transrectal biopsies. The authors suggested an improved
sampling of the PZ with the transperineal approach [80].
A contemporary prospective clinical study by Emiliozzi
et al. in which 107 patients underwent combined TRUS
sextant and 6-core “fan” transperineal biopsies, reported a
cancer detection rate of 32% and 38%, respectively. The
transperineal scheme detected 41/43 (95%) of the cancers in
the cohort [81]. However, other published series comparing
ﬁrst-time biopsies employing extended 12- and 14-core
templates have not found signiﬁcant diﬀerences between the
two approaches [82, 83]. Takenaka et al. in a prospective
randomized study comparing the diagnostic eﬃcacy of
transperineal and transrectal 12-core biopsy, found similar
overall cancer detection rates. However, the transperineal
approach was superior in the subset of patients with PSA in
t h e4 . 1 – 1 0n g / m lr a n g e[ 84].
9.TransperinealBiopsySchemesin
theRepeat/SaturationandProstate
Mapping Settings
The above studies have highlighted the importance of
improved tissue sampling by targeting the anterior prostatic
apex, the far-lateral peripheral zone, and in particular cases,
the transitional zone. Further evidence has been derived
from recent computerized models [85] and published series
of saturation protocols, involving larger number of cores
[35, 70, 77, 86, 87]. These approaches have demonstrated
their superiority in the repeated setting, where one or more
previous biopsies have failed to detect occult cancer.
In 2001, Igel et al. [88], reported their experience in
88 men with clinical suspicion of prostate cancer and, at
least, one previous negative biopsy. Systematic transperineal
biopsy detected cancer in 43% of cases, with involvement of
the TZ in 76% of cases.
Since that date, several studies on transperineal sat-
uration schemes have been published, reporting cancer
detection rates of 22.7 to 43% [86, 88–93]. With variable
number of cores, usually 20 to 30, these schemes have
still detected cancer even in highly prebiopsied cohorts.6 Prostate Cancer
Furthermore, a recent study by Li et al. [94] has evaluated
an 11-region transperineal saturation template in 303 with
clinical suspicion of prostate cancer in the ﬁrst-time setting.
With a mean of 23.7 cores (range: 11 to 44), the reported
overall cancer detection rate was 37.6%. Stratiﬁcation by
level of PSA resulted in cancer detection rates of 22.2%,
8.2%, 21.6%, 48.4%, 68.4%, and 100% for PSA levels of 0
to 4.0, 4.1 to 10.0, 10.1 to 20.0, 20.1 to 30.0, 30.1 to 70.0, and
>70.1ng/mL, respectively.
Importantly, improved early cancer detection has
resultedinadown-stageshiftwhich,pairedwiththedevelop-
ment of novel technologies and energy delivery systems, has
translated in a rapid acceptance of focal therapy of prostate
cancer as a viable therapeutic option. This has been further
supported by recent evidence that up to 20% of prostate
cancers will be completely unilateral and candidates for focal
ablation [95, 96]. However, the application of focal therapy
demands a rigorous patient selection based on a reliable
and accurate tumour-target location. In this setting, several
recently published studieshave highlighted the limitations of
sextant [97]a sw e l la se x t e n d e dt r a n s r e c t a lp r o s t a t eb i o p s y
schemes [95, 98, 99].
Mayes et al. [97] evaluated the reliability of routine
sextant biopsy to detect unilateral lesions in a cohort of
365menwho subsequentlyunderwentradical prostatectomy
(RP). When the sextant biopsy detects unilateral disease,
a c c o r d i n gt oR Pr e s u l t s ,t h eN P Vw a sh i g h( 9 1 % )w i t h
a low false-negative rate (9%). However, it has a PPV of
28% with a high false-positive rate (72%). In agreement
with other earlier [100] and contemporary [101] studies,
the authors concluded that routine sextant biopsy cannot
providereliable, accurate information about theunilaterality
of the tumour.
Tsivian et al. [95] recently published a retrospective
analysis of 882 biopsy-proven cancers (729 sextant, 153
extended biopsies) comparing sextant versus extended 12-
corebiopsy protocols. The sensitivity (from 84.1%to 88.0%)
and speciﬁcity (from 37.1% to 53.9%) improved on sextant
and extended biopsy, respectively. With a decrease in false-
positive rates from 62.9% to 46.1% and false-negative
rates from 15.9% to 12%, the overall diagnostic accuracy
increased from 49% to 59%, respectively. However, the
authors concluded that, although superior to sextant biopsy,
a 12-core scheme is not an ideal diagnostic test to select
patients for focal therapy.
On subsequent analysis of this cohort [102], including
859 patients and substratiﬁcation by prostate weight (≤40
and >40g) and biopsy scheme (6–9 sextant and 10–20 cores
extended), unilateral disease was more common in prostates
>40g both on biopsy (69% versus 60%) and on ﬁnal
pathology (21% versus 14%). In this study, extended biopsy
protocols performed better than sextant but the beneﬁt was
statistically signiﬁcant only in prostates >40g.
In response to modern diagnostic and therapeu-
tic requirements, the transperineal approach has further
evolvedtowards asophisticated staging procedure. Improved
prostate sampling can be further optimized by the use
of a ﬁxed brachytherapy grid, allowing a rigorous and
reproducible3Dmappingofthegland(3D-PMB)[103,104].
“Solid” 3D computer models reconstructed from autopsy
and T1c prostatectomy specimens have demonstrated a
superiority of the 5mm grid in cancerdetection (75% versus
33%) when compared to the 10mm grid [105].
In2008,OnikandBarzell [106]reportedtheirexperience
on 110 men with unilateral disease on TRUS biopsy,
undergoing restaging using the 3D mapping scheme prior to
focal therapy. With a median of 46 cores (SD ± 19) taken
every 5mm, this scheme detected bilateral cancer in 55%
and upgrading in 23% of cases. Updated results, including
180 cases, were published in 2009. With a median of 50 cores
(SD±20.6),bilateraldiseasewasidentiﬁedin61.1%ofcases,
with a 22.7% increase on Gleason score. Complications were
self-limited and included a 7.7% incidence of acute urinary
retention [107].
An alternative approach, aimed to exploit the advantages
ofboth,thetransrectal andthetransperineal biopsyschemes,
has recently been developed and is currently under evalua-
tion.
In 2005, Watanabe et al. [108] evaluated a 12-core
extended protocol involving a standard transrectal sextant
biopsy plus a 6-core (lateral PZ, parasagital PZ and TZ)
transperineal template. The reported overall detection rate
of 48.5% was found to be superior to either transrectal or
transperineal templates alone.
Since 2006, Kihara’s group at the Tokyo Medical and
Dental University [109–112]h a v ee x t e n s i v e l ye v a l u a t e da
more extensive sampling of the prostate combining 12-
core transrectal and 14-core transperineal biopsy templates
(3D26PB), demonstrating potential application in the stag-
ingofpatientspriortoradicalsurgery.Althoughtherewasno
signiﬁcant improvement in men with abnormal DRE (22%
improvement; P = .18), cancer detection was signiﬁcantly
improved by 85% in men with normal DRE (P = .0004)
utilizing this technique, suggesting a potential diagnostic
advantage of the 3D26 biopsy over the transrectal biopsy to
detect stage T1c disease in men with normal DRE.
10.MRI-GuidedTransperinealBiopsy
With the rapid technological development of MRI and
building on the experience acquired with MRI-guided
brachytherapy, investigators at the Brigham and Women’s
Hospital introduced an MRI-guided prostate biopsy pro-
gram, employing a transperineal approach, with direct real-
time image-guided sampling of the prostate and any suspi-
cious lesions [113–115]. The program has successfully been
performed by this group in over 50 biopsy cases, reporting
a cancer detection rate of 30% [116]. Simultaneously, a
group from the Johns Hopkins University and the National
Institutes of Health have also explored this novel technology
and performed transperineal biopsy in a series of eight
procedures in four patients, to perform a total of 32 targeted
biopsy needle placements within the prostate.With a mean
biopsy needle placement error of 2.1mm, 95% of the needle
placement errors were less than 4.0mm, demonstrating the
accuracy of modern MRI scanning in targeting prostatic
lesions [116]. This error can be further reduced with
the routine use of needles with a symmetrical bevel, asProstate Cancer 7
demonstrated by Blumenfeld et al. [117]. MR-guided biopsy,
due to its high sensitivity and higher speciﬁcity than US, has
proven to be a useful alternative to US-guided procedures
[118]. MRI guidance allows high spatial resolution and
multiplanar volumetric imaging capabilities, which can be
exploitedin selection andplanning offocaltherapies,further
enhancing the advantages of the transperineal approach.
11.Conclusion
Inthispaper,wehaveattemptedtosummarise theinteresting
evolution of the reﬁnements to prostate biopsy since Hodges
and colleagues, in 1989, ﬁrst demonstrated the superiority
of systematic TRUS biopsies, compared to digitally directed
biopsy. However, sampling limitations of this approach,
strongly evidenced with the wide introduction of PSA
testing, moved the clinicians to embrace more extended
approaches. Certainly, a 10–12 core systematic biopsy,
targeting the far lateral aspect of the peripheral zone, has
now become standard practice for initial biopsy. However,
these extended schemes have been demonstrated to be
insuﬃcient in the repeat biopsy setting. With persistent
clinical suspicion and initial negative sampling, saturation
approaches are now the preferred option by the modern
clinician, although data have demonstrated a limited value
at initial biopsy. Saturation biopsy has been favoured via a
transrectal approach as this can be performed in the oﬃce
setting, under local anaesthesia and mild sedation, with
few side eﬀects. Nonetheless, the transrectal approach has
limitations in sampling the anterior regions of the gland, in
particular the apical segment. These sampling restrictions,
together with the rapid development of minimally invasive
andinparticularfocaltherapies,havedrivenarenewedinter-
est in the transperineal approach. Despite the requirement
for general anaesthesia and a potential increased urinary
retention rate, novel transperineal mapping schemes, when
employing a brachytherapy grid template, allow for more
accurate sampling of the entire gland. The remit of prostate
biopsy now lies beyond pure diagnostics and has become
an essential tool for determining the optimal therapeutic
approach. Acomparative trial of biopsy strategies using step-
sectioned radical prostatectomy specimens should answer
outstandingquestionsanddeﬁnethefutureinthisimportant
area.
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